SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: richardred who wrote (1808)3/31/2005 11:15:14 AM
From: arnie h  Read Replies (1) of 2173
 
As I recall, the company said an FDA response is due by the end of April. The stock seems to be acting as if some kind of a negative decision has already been made and there are leaks as to the result. This would be rather surprising as the FDA has been quite good about not divulging results ahead of their formal decision. Yet, it's hard to believe the stock would sell off this much and not rebound at all without some negative news on Exenatide especially with recent Symlin approval. My guess is concern over lack of full approval at this time coupled with the Tysabri situation has led some funds to cut back. Your thoughts on options seems like the way to go. Results on Exenatide seem quite promising even if not approved next month.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News